Braidwell’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NRIX
BBA
Braidwell's NRIX Position: Q3 2026 in Review
Braidwell reduced its Nurix Therapeutics (NRIX) stake by 32% in Q3 2026, selling an estimated $10.4M and leaving 871,104 shares worth $20.7M. The position accounts for 0.86% of the portfolio, ranked #51.
Braidwell first reported a position in NRIX in Q4 2025 and has held it in 4 quarters since. The position peaked at $41.4M in Q4 2025. 233 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.
- Braidwell held 871,104 shares of Nurix Therapeutics worth $20.7M as of Q3 2026.
- Braidwell sold 415,665 Nurix Therapeutics shares in Q3 2026, an estimated $10.4M.
- Nurix Therapeutics made up 0.86% of Braidwell's portfolio in Q3 2026, its #51 holding.
- Braidwell first reported a position in Nurix Therapeutics in Q4 2025 and has held it in 4 quarters since.
- Braidwell's Nurix Therapeutics position peaked at $41.4M in Q4 2025.
- 233 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.
Based on Braidwell's 13F filing for Q3 2026, filed 16 Nov 2026.